Mounjaro Dosage/Direction for Use

Posology: The starting dose of tirzepatide is 2.5 mg once weekly. After 4 weeks, the dose should be increased to 5 mg once weekly. If needed, dose increases can be made in 2.5 mg increments after a minimum of 4 weeks on the current dose.
The recommended maintenance doses are 5, 10 and 15 mg.
The maximum dose is 15 mg once weekly.
When tirzepatide is added to existing metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy, the current dose of metformin and/or SGLT2i can be continued.
When tirzepatide is added to existing therapy of a sulphonylurea and/or insulin, a reduction in the dose of sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia. Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and insulin. A stepwise approach to insulin reduction is recommended (see Precautions and Adverse Reactions).
For weight management, if patients have been unable to lose at least 5% of their initial body weight 6 months after titrating to the highest tolerated dose, a decision is required on whether to continue treatment, taking into account the benefit/risk profile in the individual patient (see Pharmacology: Pharmacodynamics under Actions).
Missed doses: If a dose is missed, it should be administered as soon as possible within 4 days after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
Changing the dosing schedule: The day of weekly administration can be changed, if necessary, as long as the time between two doses is at least 3 days.
Special populations: Elderly, gender, race, ethnicity or body weight: No dose adjustment is needed based on age, gender, race, ethnicity or body weight (see Precautions, and Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions).
Renal impairment: No dose adjustment is required for patients with renal impairment including end stage renal disease (ESRD). Experience with the use of tirzepatide in patients with severe renal impairment and ESRD is limited. Caution should be exercised when treating these patients with tirzepatide (see Pharmacology: Pharmacokinetics under Actions).
Hepatic impairment: No dose adjustment is required for patients with hepatic impairment. Experience with the use of tirzepatide in patients with severe hepatic impairment is limited. Caution should be exercised when treating these patients with tirzepatide (see Pharmacology: Pharmacokinetics under Actions).
Paediatric population: The safety and efficacy of tirzepatide in children aged less than 18 years have not yet been established. No data are available.
Method of administration: Mounjaro is to be injected subcutaneously in the abdomen, thigh or upper arm.
The dose can be administered at any time of day, with or without meals.
Injection sites should be rotated with each dose. If a patient also injects insulin, they should inject Mounjaro into a different injection site.
Patients should be advised to carefully read the instructions for use and the package leaflet for the pre-filled KwikPen before administering the medicinal product.
For further information before administration see Special precautions for disposal under Cautions for Usage.